| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.hikal.com | |
| Market Cap | 3,667.58 Cr. | |
| Enterprise Value(EV) | 4,404.91 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 5.81 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 51.20 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 42.14 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 94.19 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 3.16 | Calculated using Price: 297.45 |
| Dividend Yield | 0.40 | Period Ending 2023-03 |
| No. of Shares Subscribed | 12.33 Cr. | 123,300,750 Shares |
| FaceValue | 2 | |
| About Hikal Ltd. | ||
| Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA. | ||
| 1 Day |
|
-1.83% |
| 1 Week |
|
-3.76% |
| 1 Month |
|
+4.26% |
| 3 Month |
|
+2.22% |
| 6 Month |
|
+6.24% |
| 1 Year |
|
+0.19% |
| 2 Year |
|
-21.94% |
| 5 Year |
|
+69.38% |
| 10 Year |
|
+327.67% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 9.81 | 9.32 | 12.74 | 12.12 | 14.46 | 10.74 | 15.22 | 16.04 | 7.12 | |
| Return on Capital Employed (%) | 12.5 | 11.92 | 11.87 | 12.81 | 15.25 | 12.44 | 16.15 | 15.21 | 8.47 | |
| Return on Assets (%) | 3.12 | 3.17 | 5.02 | 5.15 | 6.11 | 4.62 | 6.84 | 7.39 | 3.27 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 532 | 564 | 605 | 669 | 756 | 817 | 933 | 1,068 | 1,133 | 1,145 | |
| Non Curr. Liab. | 242 | 337 | 324 | 312 | 359 | 410 | 379 | 432 | 646 | 546 | |
| Curr. Liab. | 530 | 397 | 470 | 616 | 659 | 653 | 703 | 828 | 691 | 699 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 1,304 | 1,298 | 1,400 | 1,597 | 1,775 | 1,879 | 2,016 | 2,328 | 2,471 | 2,391 | |
| Non Curr. Assets | 791 | 808 | 793 | 851 | 888 | 1,048 | 1,091 | 1,305 | 1,502 | 1,497 | |
| Curr. Assets | 513 | 490 | 607 | 746 | 886 | 831 | 925 | 1,023 | 968 | 894 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 1,304 | 1,298 | 1,400 | 1,597 | 1,775 | 1,879 | 2,016 | 2,328 | 2,471 | 2,391 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 872 | 926 | 1,014 | 1,296 | 1,590 | 1,507 | 1,720 | 1,943 | 2,023 | 1,816 | |
| Other Income | 2 | 2 | 3 | 4 | 2 | 4 | 5 | 5 | 5 | 2 | |
| Total Income | 873 | 927 | 1,017 | 1,301 | 1,592 | 1,511 | 1,725 | 1,948 | 2,028 | 1,818 | |
| Total Expenditure | -689 | -745 | -815 | -1,054 | -1,291 | -1,234 | -1,398 | -1,602 | -1,766 | -1,555 | |
| PBIDT | 184 | 183 | 202 | 246 | 300 | 277 | 328 | 345 | 262 | 263 | |
| Interest | -60 | -62 | -48 | -49 | -58 | -52 | -36 | -31 | -48 | -54 | |
| Depreciation | -64 | -67 | -69 | -86 | -93 | -82 | -85 | -96 | -109 | -112 | |
| Taxation | -19 | -12 | -13 | -34 | -46 | -42 | -73 | -58 | -27 | -25 | |
| Exceptional Items | -4 | -15 | |||||||||
| PAT | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 161 | 78 | 72 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 40 | 41 | 68 | 77 | 103 | 84 | 133 | 161 | 78 | 72 | |
| Adjusted EPS | 3 | 3 | 5 | 6 | 8 | 7 | 11 | 13 | 6 | 6 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 154 | 102 | 186 | 163 | 139 | 186 | 285 | 229 | 294 | 315 | |
| Cash Fr. Inv. | -23 | -43 | -64 | -102 | -110 | -125 | -164 | -156 | -284 | -292 | |
| Cash Fr. Finan. | -124 | -69 | -124 | -63 | -25 | -55 | -101 | -97 | -6 | -8 | |
| Net Change | 7 | -10 | -2 | -2 | 4 | 6 | 20 | -24 | 4 | 15 | |
| Cash & Cash Eqvt | 16 | 6 | 4 | 2 | 6 | 11 | 32 | 8 | 11 | 27 |
|
Fri, 03 May 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Earnings Conference call to discuss the financial and operational performance for the period ended Q4 & FY24 |
|
Thu, 02 May 2024
Board Meeting Intimation for Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31 2024 And Recommendation Of Final Dividend If Any. HIKAL LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 inter alia to consider and approve 1) the audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended on March 31 2024 along with the statements of assets and liabilities and the cash flow statement as on that date; 2) the audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on March 31 2024; 3) Recommendation of payment of final dividend if any for the financial year 2023-24 for the approval of shareholders at the 36th Annual General Meeting of the Company. |
|
Thu, 02 May 2024
Corporate Action-Board to consider Dividend To recommend the payment of final dividend for the financial year 2023-24 if any for the approval of shareholders at the 36th Annual General Meeting of the Company |
| Fri, 03 May 2024 |
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week High Zone
|
CCI Trending Down
|
RSI Trending Down
|
